Baird Maintains Outperform on Leap Therapeutics, Lowers Price Target to $20
Portfolio Pulse from jenniferd'souza@benzinga.com
Baird analyst Joel Beatty has maintained an Outperform rating on Leap Therapeutics (NASDAQ:LPTX), but lowered the price target from $30 to $20.
August 15, 2023 | 12:55 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Leap Therapeutics' price target has been lowered from $30 to $20 by Baird, though the Outperform rating is maintained.
The lowering of the price target by Baird indicates a potential decrease in the stock's value. However, the maintained Outperform rating suggests that the stock is still expected to outperform the market, which could mitigate some of the negative impact.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100